0001209191-20-048864.txt : 20200831 0001209191-20-048864.hdr.sgml : 20200831 20200831204114 ACCESSION NUMBER: 0001209191-20-048864 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200828 FILED AS OF DATE: 20200831 DATE AS OF CHANGE: 20200831 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Munshi Amit CENTRAL INDEX KEY: 0001612551 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31161 FILM NUMBER: 201153121 MAIL ADDRESS: STREET 1: C/O EPIRUS BIOPHARMACEUTICALS, INC. STREET 2: 699 BOYLSTON STREET, 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARENA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001080709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232908305 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-453-7200 MAIL ADDRESS: STREET 1: 6154 NANCY RIDGE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-28 0 0001080709 ARENA PHARMACEUTICALS INC ARNA 0001612551 Munshi Amit C/O ARENA PHARMACEUTICALS, INC. 6154 NANCY RIDGE DRIVE SAN DIEGO CA 92121 1 1 0 0 President and CEO Common Stock 2020-08-28 4 M 0 50000 15.50 A 57750 D Common Stock 2020-08-28 4 S 0 50000 70.00 D 7750 D Common Stock 2020-08-31 4 M 0 50000 15.50 A 57750 D Common Stock 2020-08-31 4 S 0 50000 70.1007 D 7750 D Employee Stock Option (right to buy) 15.50 2020-08-28 4 M 0 50000 0.00 D 2023-05-11 Common Stock 50000 288139 D Employee Stock Option (right to buy) 15.50 2020-08-31 4 M 0 50000 0.00 D 2023-05-11 Common Stock 50000 238139 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4. The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested. /s/ Andrew J. Cronauer, as Attorney-in-Fact 2020-08-31